Trump’s Remarks Shake Weight Loss Drug Stocks but Reveal Long-Term Opportunities

After-hours trading in U.S. markets saw shares of weight-loss and diabetes drug makers tumble. A statement from President Donald Trump that has investors rethinking profit expectations.

In a White House press briefing, Trump said that popular weight-loss drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro would see significant price reductions. The announcement sent stocks of GLP-1 drug makers sharply lower.

Understanding GLP-1 Drugs

If you’re not familiar, GLP-1 is a class of medications that help regulate blood sugar and aid in weight loss. Originally designed for type 2 diabetes, these drugs have become a blockbuster for weight management due to their strong appetite-suppressing and metabolism-boosting effects.

Key examples:

• Eli Lilly’s Mounjaro and Zepbound contain Tirzepatide

• Novo Nordisk’s Ozempic and Wegovy contain Semaglutide

These medications are effective at controlling blood sugar and reducing weight, which is why their prices have been high and why investors watch them closely.

Who Was Affected Most

In after-hours trading:

• Eli Lilly $LLY  dropped about 4.6% to $781.50

• Novo Nordisk $NVO fell about 3.7% to $53.99

• Hims & Hers Health $HIMS  declined about 2.3% to $57.80

Hims & Hers offers compounded drugs, which are lower-cost versions allowed when the original medication faces shortages. In 2024, GLP-1 sales generated over $225 million in revenue for the company.

Why Trump’s Words Matter

Stock prices reflect future profit expectations. Investors worry that if prices drop, margins could shrink, impacting earnings and causing stocks to fall. This is a classic case of policy or public statements driving market expectations, especially in high-demand, price-sensitive sectors like weight-loss drugs.

What This Means for Investors

1. Short-term swings don’t always reflect long-term risk
   Even if prices fall, demand for GLP-1 drugs remains strong. These medications are likely to stay central in diabetes and obesity treatment.

2. Policy changes may broaden market access and create growth opportunities
   Lower prices could expand usage, boosting overall sales. Large players like Eli Lilly and Novo Nordisk might feel short-term pressure, but they have strong competitive advantages that make them resilient.

3. Smaller companies could benefit from market expansion
   Hims & Hers, focusing on affordable compounded drugs, may gain market share as more patients can access these treatments. Price reductions don’t necessarily mean lower sales—it could mean faster adoption for smaller players.

The Bottom Line

This sell-off appears to be a market reaction to news rather than a change in fundamentals. Understanding the underlying value of the drugs, the size of the market, and the impact of policy is key for investors. Short-term price swings are just that—short-term.

For those willing to look past the headlines, there may be compelling opportunities in both the established leaders and the smaller innovators in the GLP-1 space.